Navigation Links
Omeros Reports Allowance of Additional Patent for Arthroscopic Product
Date:5/24/2011

SEATTLE, May 24, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming the composition of OMS103HP, the Company's arthroscopic PharmacoSurgery™ product in Phase 3 clinical development.  The patent will have a term extending into January 2020.

"This patent extends coverage for OMS103HP and adds to our established intellectual property portfolio for our PharmacoSurgery platform," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.  "The clinically meaningful and statistically significant improvement in postoperative knee function seen in our Phase 2 meniscectomy trial played a role in the USPTO's decision.  The drug is now in a Phase 3 meniscectomy program and we expect data in the first half of 2012."

Omeros is preparing additional patent applications directed to OMS103HP that would further extend its patent protection until at least 2032.

Omeros' OMS103HP Program

OMS103HP is Omeros' PharmacoSurgery™ product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), each with well-known safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles.

In a Phase 2 clinical trial that evaluated OMS103HP in patients undergoing partial meniscectomy surgery, OMS103HP provided clinically meaningful and sig
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Clinical Development Programs for OMS103HP and OMS302
2. Omeros Corporation Reports First Quarter 2011 Financial Results
3. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
4. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
5. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
6. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
7. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
8. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
9. Omeros Announces Publication of Data From Antifibrinolytic Program
10. Omeros Licenses Novel Antifibrinolytic Agents
11. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... VIEJO , Kalifornien, 28. August ... hat heute den Start der Patientenrekrutierung ... Device Exemption, Forschungsausnahmegenehmigung) zur Beurteilung der ... zur Embolisation von Aneurysmen („WEB") bekanntgegeben. Adam ... of Tennessee, Department of Neurosurgery/Semmes-Murphey Clinic, ...
(Date:8/28/2014)... , Aug. 28, 2014 The ... entered a partnership to advance an experimental cancer ... (SMM), an asymptomatic stage of myeloma. ... (TAP), through which LLS forges collaborations with biotechnology ... OncoPep is developing a vaccine, ...
(Date:8/28/2014)... 2014  STAAR Surgical Company (NASDAQ: STAA ) ... delivery systems for the eye, today announced that management will ... New York Palace Hotel on Wednesday, September 3 at 7:15 ... President and CEO will offer a general overview of the ... be joined by Steve Brown , CFO, and ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2STAAR Surgical To Present At The Baird 2014 Health Care Conference 2
... turned in nearly 5,500 pounds of prescription and over-the-counter ... offices throughout the state during the Drug Take Back ... amount dropped off at 38 sites last year. As ... National Association of Drug Diversion Investigators (NADDI) and ...
... 1, 2011 Vikes, Dance Fever, French Fries. The names ... your kids have heard of them. These are the street ... using them to get high. To view ... http://multivu.prnewswire.com/mnr/besmartbewell/50821/ (Logo: http://photos.prnewswire.com/prnh/20110901/MM60576LOGO ) ...
Cached Medicine Technology:NADDI and the C.A.R.E.S. Alliance Co-Sponsor Successful Drug Take Back Day 2Is Your Teen Getting High on Your Prescription? 2Is Your Teen Getting High on Your Prescription? 3
(Date:8/28/2014)... Albany, New York (PRWEB) August 28, 2014 ... is currently perceived with great interest among other healthcare ... due to the high demand in vaccine with respect ... also highly in demand due to an improved understanding ... individuals across the United States. It has led to ...
(Date:8/28/2014)... After more than two years of ... excited to announce the opening of Houston’s Mirror Mirror ... city, Mirror Mirror Beauty Boutique offers premium aesthetic services ... corner of Richmond and Drexel near Highland Village, Mirror ... cutting-edge technology in a private, easy to access location. ...
(Date:8/28/2014)... Steven Reinberg HealthDay ... Treating pre-cancerous skin spots with a type of light therapy ... the lesions with liquid nitrogen, a new study suggests. ... the scalp and face of people with fair complexions who,ve ... of prior research found that people who underwent the light ...
(Date:8/28/2014)... August 28, 2014 Genetic testing ... throughout the world, with large reference laboratories as ... laboratories differ with regard to the genetic variants ... payers may struggle to find the most appropriate ... help clients sort through these differences, Hayes, Inc. ...
(Date:8/28/2014)... Hastings and Hastings, a Phoenix Arizona accident lawyer ... industry is pleased to report having saved a client ... This is exciting news for existing clients and prospective ... proof that Hastings and Hastings stands behind its claim ... clients money when it comes to settlements and recoveries ...
Breaking Medicine News(10 mins):Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 2Health News: Light Therapy a Good Option for Pre-Cancerous Skin Lesions, Study Says 3Health News:Hayes, Inc. Unveils Laboratory Comparison Tables for GTE Clients 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $13,750 On A Settlement Of $125,000 3
... MARCH 17, 2009 The medical costs that businesses pay ... cover the costs for nearly a dozen healthy, full-term infants, ... , The average medical cost for healthy full-term babies from ... of which more than $3,800 is paid for by health ...
... 17 JumpStart Inc. , the ... of high growth early-stage businesses, and Case Technology ... technology validation fund at Case Western Reserve University ... Neuros Medical, Inc. , a Cleveland, OH company ...
... Research Group, Inc. has been covering the biologics market ... series which are syndicated primary research reports ... and Rheumatologists. The company is now expanding these ... reports which aim to compare self-reported treatment patterns ...
... device in Mexico for Minimally Invasive Treatment for ... from elite urologistsCHARLOTTE, N.C., March 16 Mexico ... and international entities of USHIFU, a global leader ... intensity focused ultrasound (HIFU) technologies, will host the ...
... Scientific, Inc. (Nasdaq: STSI ) filed its ... and Exchange Commission. The company reported 2008 net sales ... sales for 2007. However, volume sales of the company,s ... 7.8% in 2008 compared to 2007. The wholesale price ...
... /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... Company is calling its $12.4 million of 10.0% Secured,Promissory ... In addition, the,Company announced the completion of the following ... million in principal amount 10.0% senior secured, ...
Cached Medicine News:Health News:Medical costs for one premature baby could cover a dozen healthy births 2Health News:Medical costs for one premature baby could cover a dozen healthy births 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:High Intensity Focused Ultrasound Physician Training Seminar in Mexico City 2Health News:Star Scientific Files Annual Financial Report 2Health News:Star Scientific Files Annual Financial Report 3Health News:Star Scientific Files Annual Financial Report 4Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: